OTCMKTS:MCUJF Medicure Earnings Date & Estimates $3.05 -0.10 (-3.17%) As of 11:20 AM Eastern Medicure is estimated to report earnings on Thursday, November 19, 2026, after market closes. Research:ProfileEarnings History Upcoming Earnings Announcement Announcement DateNovember 19, 2026TimeAfter Market Closes Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from MedicureMedicure is expected to post earnings of -$0.0220 per share on revenue of $3.56 million. In the same quarter a year earlier Medicure reported -$0.09 per share on revenue of $5.93 million. Medicure last reported on August 14, 2026, posting -$0.10 per share and missing the -$0.0474 consensus estimate.Consensus EstimatesConsensus EPS-$0.0220Expected Revenue$3.56 millionPrior-Year EPS-$0.09Prior-Year Revenue$5.93 millionExpected Revenue Growth-40.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.10 (Missed by -$0.0526)Last Quarter Revenue$5.36 millionPrepare for the Earnings CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Medicure Earnings FAQ When does Medicure report earnings? Medicure (OTCMKTS:MCUJF) is estimated to report earnings on Thursday, November 19, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Medicure? Analysts expect Medicure to post earnings of -$0.0220 per share for the quarter. How much revenue is Medicure expected to report? The consensus revenue estimate for Medicure is $3.56 million for the quarter. Medicure Earnings HeadlinesMedicure (OTCMKTS:MCUJF) Stock Price Breaks Above 50-Day Moving Average - Should You Sell?October 20, 2026 | americanbankingnews.comMEDICURE : ANNOUNCES GRANT OF STOCK OPTIONSOctober 1, 2026 | marketscreener.comMTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years.October 27 at 1:00 AM | Porter & Company (Ad)Medicure, Inc.: Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical TrialSeptember 28, 2026 | finanznachrichten.deMedicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...May 26, 2026 | finance.yahoo.comMedicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference CallMay 21, 2026 | finanznachrichten.deSee More Medicure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email. Email Address About MedicureMedicure (OTCMKTS:MCUJF) is a Canadian pharmaceutical company focused on developing and commercializing therapies for cardiovascular and related serious medical conditions. The company is headquartered in Winnipeg, Manitoba, and serves healthcare markets primarily through its U.S. pharmaceutical operations. Medicure’s principal commercial product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used to help reduce thrombotic cardiovascular events in patients with acute coronary syndromes, including non-ST-segment elevation acute coronary syndrome. The product is marketed to hospitals and other healthcare providers. In addition to supporting AGGRASTAT, Medicure has pursued the development and commercialization of additional cardiovascular medicines and related healthcare products. The company’s activities have historically emphasized specialized hospital therapies and addressing unmet needs in cardiovascular care. Specific current leadership information was not included because reliable details were not available.View Medicure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Whirlpool's Stock Collapse Raises a Bigger Question About Its Recovery PotentialAnalysts Turn Bullish on Meta Platforms Despite Post-Earnings FallLockheed Martin's F-35 Deal Could Change How Wall Street Values the StockIntel's $155 Price Target Raises a Bigger Question About Its Turnaround PotentialMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid?Approaching Earnings Season, Are Pure Play Quantum Stocks Still a Good Bet?GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy Upcoming Earnings T-Mobile US (10/28/2026)Alphabet (10/28/2026)Alphabet (10/28/2026)Carvana (10/28/2026)eBay (10/28/2026)Garmin (10/28/2026)O'Reilly Automotive (10/28/2026)Equinor ASA (10/28/2026)Phillips 66 (10/28/2026)AON (10/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
